Hong Jin，CSO, CyanVac, USA
PIV5-Vectored RSV and COVID-19 Intranasal Vaccines Show Great Promise in Clinical Studies
Vaccine Innovation Forum（VIF） World 2025 第6届疫苗创新国际论坛
邀您共同打造 亚洲最大的专业疫苗国际大会！
120+演讲嘉宾 1000+参会代表 60+展商 30+国家和地区
持续推动中国与国际疫苗科学、市场的交流及合作
时间：2025年3月20-22日 地点：中国 上海
科学顾问委员会： Bin Wang，艾棣维欣创始人 /复旦大学特聘教授 George Fu Gao, 中科院院士，教授 David Weiner，Wistar研究所执行副总裁；美国宾夕法尼亚大学名誉教授 Chunlin Xin，康希诺生物副总裁， Yuanqing Liu，嘉晨西海中国CSO Heinrich Haas，BioNtech制剂和药物递送前副总裁， Alain Bouckenooghe,Hilleman Laboratories CSO Shaowei Li，厦门大学教授 Amine Kamen,加拿大麦吉尔大学教授 Kiat Ruxrungtham，泰国朱拉隆功大学Chula疫苗研究中心主任 Dexiang Chen，迈科康生物董事长兼总经理 Anna Du，比尔及梅琳达盖茨基金会中国国家办事处高级项目官员 Li Shi，怡道生物董事长 Sean Du，赛诺菲巴斯德全球研发部亚太地区外部研发部负责人 Yuan Yuan，PATH中国国家代表，业务和联盟管理负责人 Petro Terblanche，南非Afrigen Biologics CEO Linqi Zhang，清华大学教授
Xiaofeng Liang，中华预防医学会副会长，暨南大学教授
Yuelong Shu, 中国医学研究院病原生物学研究所所长 Diana Baraschi,意大利国家研究委员会院士，中国科学院深圳先进技术研究院特聘教授
Emanuele Montomoli, 意大利Siena大学教授/VisMederi创始人&首席科学家 Joon Haeng Rhee，韩国全南国立大学医学院教授 Michel De Wilde，赛诺菲巴斯德研发部前SVP George Siber，Siber Biotechnologies总裁，约翰霍普金斯大学终身教授 Raman Rao, 新加坡Hilleman Laboratories CEO Meng Li, 中国生物国际合作部主任 Ruben Rizzi, BioNTech全球法规事务高级副总裁 Huichen Guo, 兰州兽医研究所研究员
Ken Ishii,日本国际疫苗设计中心主任，东京大学教授
往届回顾： ![]()
参会嘉宾评价：
![]()
![]()
主要话题：
创新疫苗开发进展
新疫苗平台和技术
基于RNA技术的疫苗及疗法
动物疫苗
癌症疫苗与免疫疗法
生物工艺和制造
临床试验与疫苗安全性
市场准入、监管和国际合作
佐剂、制剂和递送技术
全球健康与疾病防控
80+早期确认嘉宾：
Ruben Rizzi, Senior Vice President Global Regulatory Affairs，BioNTech, Germany
Francesca Ceddia, Chief Medical Affairs Officer, Moderna, USA
Zihao Wang, CEO, Immorna Bio, China
Francesco Berlanda Scorza, VP, R&D, Global Health R&D Vaccines Head and GVGH Institute Director, GSK, Italy
Bo Ying, Co-founder, Chairman&CEO, Abogen Biosciences, China
Pardi Norbert,Assistant Professor, University of Pennsylvania, USA
Kate Broaderick, Cheif Innovation Officer, Maravai Life Science
Robbert van der Most, Former VP, Translational Science Infectious Diseases, BioNTech, CEO, VaxxCellence,Belgium
Heinrich Hass, Former VP, Formulation& Delivery, BioNtech;CTO, NeoVac, UK
Jiangsheng Xu, Co-founder&CSO, General Therapeutics, USA
Yelin Xiong, VP, Yither Biotech, China
Kiat Ruxrungtham, Professor of Medicine, Director of Chula VRC, Chulalongkorn University, Thailand
Petro Terblanche, CEO, Afrigen Biologics, South Africa
George Fu Gao, Former Director, China CDC; Academician,Professor, Chinese Academy of Sciences
Rajinder Suri, CEO, DCVMN International, Switzerland
Raches Ella, Chief Development Officer, Bharat Biotech, India
Hun Kim, President of Global Biz, SK bioscience, South Korea
Mahesh Kumar, SVP of R&D, Global Biologics, Zoetis, USA
Simon Graham, Professor, The Pirbright Institute, UK
Jidong Cui, Unit Head, Local Production & Assistance Unit, Innovation and Emerging Technologies Department
(IET),MHP, World Health Organization, Switzerland
Emanuel Montomoli, Professor, Full Prof. of Public Health, University of Siena;CSO of VisMederi Italy
George Siber, President, Siber Biotechnologies LLC, USA
Joon Haeng Rhee, Professor, Chonnam National University Medical School, South Korea
Diana Boraschi, Distinguished Professor, Shenzhen Institute of Advanced Technology, China
Melanie Saville, CSO, PATH, USA
Ken Ishii, Director, International Vaccine Design Center, Professor, University of Tokyo, Japan
Nikolai Petrovsky, Founder, Vaxine, Australia
Adrian V. S. Hill, Director, The Jenner Institute, Lakshmi Mittal & Family Professor of Vaccinology, University of Oxford , UK
Raman Rao, CEO, the Hilleman Laboratories, Singapore
Meng Li, Head of Board Office, Director of International Cooperation, China National Biotec Group, China
Bin Wang, Professor, Fudan University/Founder, Advaccine, China
Linqi Zhang, Professor, Tsinghua University, China
Shaowei Li, Professor, Xiamen University, China
Nigel Temperton, Professor, Director, Viral Pseudotype Unit, University of Kent, UK
Xiaofeng Liang, VP, Chinese Preventive Medicine Association; Professor, Jinan University, China
Tongqing Zhou, Chief, Structural Bioinformatics Section National Institutes of Health, USA
Shibo Jiang, Professor, Fudan University, China
Wei Tan, SVP, Head of China Research and External Collaboration, Clover Biopharmaceutical, China
Huichen Guo, Professor, Lanzhou Veterinary Research Institute, China
Baik-Lin Seong, Director General, Vaccine Innovative Technogy ALliance (VITAL)-Korea, South Korea
Christopher Netherton, Professor, The Pirbright Institute, UK
Nibal Dahaba, Co-Founder & General manager Emerging markets，Gennecs Holding, Egypt
Jiguo (Jeffrey) Zhang, President, Vaccine Division, Fosun Pharma, China
Zhaohua (Jessie) Chen, Head of Development China, General Manager of Pfizer China R&D, China
Yuelong Shu, Director, Institute of Pathogen Biology, CAMS & PUMC, China
Jingxin Li, Vice Director of the Department, Jiangsu CDC, China
Linfa Wang, Professor, Duke-NUS Medical School, Singapore
Dan Barouch, Professor, Harvard Medical School, USA
Nicaise Ndembi, Head for Partnerships for African Vaccine Manufacturing (PAVM) & Head Science Office, Africa CDC, Ethiopia
Yunlong Richard Cao, Assistant Professor, Peking University, China
Amine Kamen, Professor, McGill University, Canada
Lianpan Dai, Professor, Institute of Microbiology, Chinese Academy of Sciences, China
Han Wang, Associate Professor, Peking University, China
Patrícia Neves, Project Manager, mRNA center,Bio-Manguinhos/ Fiocruz, Brazil
Adel Sattarova, Head of Project activity department, FSUE SPbSRIVS FMBA of Russia
SeyedReza Banihashemi, Director of R&D,Razi Vaccine & Serum Research Institute, Iran
Hani Kim, Executive Director, RIGHT Foundation, South Korea
Jian Dong, CEO, WuXi Vaccines; SVP, WuXi Biologics, China
Qihan Li, Professor, Weirui Bio, China
Sean Du, Head, External R&D APAC, Global R&D, Sanofi Pasteur, China
Landian Hu, CEO, Anda Biology Medicine Development (Shenzhen)
Adham Rezk, CEO, Celero, Singapore
Hong Jin, CSO, CyanVac, USA
Nguyen Tuyet Nga, South East Asia Hub Director/Vietnam Country Director, PATH, Vietnam
Peter L. Andersen, Chief Scientific Advisor, Infectious Diseases,Novo Nordisk Foundation, Denmark
Xiangrong Song, Cofounder& CEO, Westgene, China
Jie Li, Head of R&D, The Spirit Jinyu Biological Pharmaceutical, China
SuthiraTaychakhoonavudh，CEO,Baiya Phytopharm, Thailand
Dexiang Chen, CEO, Maxvax, China
Deog-Young Choi, CEO, InThera, South Korea
Peter Dull, Deputy Director at Bill & Melinda Gates Foundation, USA
Emanuele Andreano, Project Leader, Fondazione Toscana Life Sciences,
Italy
Hao Chen, AVP, Head of Vaccines & Advanced Biotechnologies Process R&D, Merck, USA
Hao Li, Associate Professor, China Agricultural University, China
Xuexiang Han, Professor, SIBCB, China
Haibo Li, Professor, Army Medical University, China
Ying Mazzu, COB&CSO, Nanjing AuroRNA Biotechnology, China
Frank Chang, CTO, Reber Genetics, China
Keith Chappel, Group Leader, The University of Queensland, Australia
更多嘉宾正在赶来，不容错过！
会议官网、报名
![]()
Poster申请
![]()
赞助、展览及商务合作 ![]()
团队报名、进群及其他事宜， 请联系主办方：13482341046 Sam
会议主办方：ChStone Events
